false000183003312/312023Q150P3DP3D00018300332023-01-012023-03-310001830033us-gaap:CommonStockMember2023-01-012023-03-310001830033us-gaap:WarrantMember2023-01-012023-03-310001830033us-gaap:MemberUnitsMember2023-01-012023-03-3100018300332023-05-05xbrli:shares00018300332023-03-31iso4217:USD00018300332022-12-31iso4217:USDxbrli:shares00018300332022-01-012022-03-310001830033us-gaap:CommonStockMember2022-12-310001830033us-gaap:AdditionalPaidInCapitalMember2022-12-310001830033us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001830033us-gaap:RetainedEarningsMember2022-12-310001830033us-gaap:CommonStockMember2023-01-012023-03-310001830033us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001830033us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001830033us-gaap:RetainedEarningsMember2023-01-012023-03-310001830033us-gaap:CommonStockMember2023-03-310001830033us-gaap:AdditionalPaidInCapitalMember2023-03-310001830033us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001830033us-gaap:RetainedEarningsMember2023-03-310001830033us-gaap:CommonStockMember2021-12-310001830033us-gaap:AdditionalPaidInCapitalMember2021-12-310001830033us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001830033us-gaap:RetainedEarningsMember2021-12-3100018300332021-12-310001830033us-gaap:CommonStockMember2022-01-012022-03-310001830033us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001830033us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001830033us-gaap:RetainedEarningsMember2022-01-012022-03-310001830033us-gaap:CommonStockMember2022-03-310001830033us-gaap:AdditionalPaidInCapitalMember2022-03-310001830033us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001830033us-gaap:RetainedEarningsMember2022-03-3100018300332022-03-3100018300332021-03-172021-03-1700018300332021-03-17pct:tradingDay0001830033us-gaap:PrivatePlacementMember2022-03-070001830033us-gaap:PrivatePlacementMemberpct:SeriesAWarrantsMember2022-03-070001830033us-gaap:CommonStockMemberus-gaap:PrivatePlacementMember2022-03-172022-03-170001830033us-gaap:PrivatePlacementMemberpct:SeriesAWarrantsMember2022-03-170001830033us-gaap:PrivatePlacementMember2022-03-172022-03-1700018300332022-03-172022-03-170001830033us-gaap:RevolvingCreditFacilityMember2023-03-150001830033pct:IrontonFacilityMembersrt:MinimumMember2023-03-310001830033srt:MaximumMemberpct:IrontonFacilityMember2023-03-310001830033pct:IrontonFacilityMember2023-03-310001830033pct:AugustaFacilityMember2023-03-310001830033pct:FeedPrepFacilitiesMember2023-03-310001830033us-gaap:SubsequentEventMemberpct:PurePlasticTermLoanFacilityMember2023-05-08xbrli:pure0001830033us-gaap:SubsequentEventMember2023-05-080001830033pct:RevenueBondsMember2020-10-07pct:series0001830033pct:RevenueBondsMemberpct:A2020ABondSeriesMaturingDecember12025Member2020-10-070001830033pct:A2020ABondSeriesMaturingDecember12030Memberpct:RevenueBondsMember2020-10-070001830033pct:RevenueBondsMemberpct:A2020ABondSeriesMaturingDecember12042Member2020-10-070001830033pct:A2020BBondSeriesMaturingDecember12025Memberpct:RevenueBondsMember2020-10-070001830033pct:RevenueBondsMemberpct:A2020BBondSeriesMaturingDecember12027Member2020-10-070001830033pct:A2020CBondSeriesMaturingDecember12027Memberpct:RevenueBondsMember2020-10-070001830033pct:RevenueBondsMember2021-03-170001830033pct:RevenueBondsMember2022-01-310001830033pct:RevenueBondsMember2023-01-012023-03-310001830033pct:RevenueBondsMember2022-01-012022-03-310001830033pct:RevenueBondsMember2023-03-3100018300332020-10-07pct:supplierpct:purchaser0001830033pct:IrontonFacilityMember2023-03-15utr:lb0001830033pct:IrontonFacilityMembersrt:MinimumMember2023-03-150001830033us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberpct:DebtInstrumentApplicableMarginPeriodOneMember2023-03-152023-03-150001830033us-gaap:RevolvingCreditFacilityMemberpct:DebtInstrumentApplicableMarginPeriodTwoMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-03-152023-03-150001830033us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberpct:DebtInstrumentApplicableMarginPeriodThreeMember2023-03-152023-03-150001830033us-gaap:RevolvingCreditFacilityMemberpct:DebtInstrumentApplicableMarginPeriodFourMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-03-152023-03-150001830033us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberpct:DebtInstrumentApplicableMarginPeriodFiveMember2023-03-152023-03-150001830033us-gaap:RevolvingCreditFacilityMember2023-03-152023-03-150001830033us-gaap:RevolvingCreditFacilityMember2023-03-310001830033us-gaap:RevolvingCreditFacilityMember2023-03-162023-03-31pct:vote0001830033pct:A2021EquityAndIncentiveCompensationPlanMember2021-03-170001830033pct:A2021EquityAndIncentiveCompensationPlanMember2023-03-310001830033us-gaap:RestrictedStockUnitsRSUMember2021-12-310001830033us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-12-310001830033us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001830033us-gaap:RestrictedStockUnitsRSUMember2022-03-310001830033us-gaap:RestrictedStockUnitsRSUMember2022-12-310001830033us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-12-310001830033us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001830033us-gaap:RestrictedStockUnitsRSUMember2023-03-310001830033us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001830033us-gaap:EmployeeStockOptionMember2022-01-012022-03-3100018300332021-01-012021-12-3100018300332022-01-012022-12-310001830033us-gaap:PerformanceSharesMember2023-01-012023-03-310001830033us-gaap:PerformanceSharesMember2022-01-012022-03-310001830033us-gaap:PerformanceSharesMember2021-12-310001830033us-gaap:PerformanceSharesMember2021-01-012021-12-310001830033us-gaap:PerformanceSharesMember2022-03-310001830033us-gaap:PerformanceSharesMember2022-12-310001830033us-gaap:PerformanceSharesMember2022-01-012022-12-310001830033us-gaap:PerformanceSharesMember2023-03-310001830033us-gaap:CommonStockMember2022-03-172022-03-170001830033us-gaap:CommonStockMember2021-12-310001830033us-gaap:CommonStockMember2021-01-012021-12-310001830033us-gaap:CommonStockMember2022-01-012022-03-310001830033us-gaap:CommonStockMember2022-03-310001830033us-gaap:CommonStockMember2022-12-310001830033us-gaap:CommonStockMember2022-01-012022-12-310001830033us-gaap:CommonStockMember2023-01-012023-03-310001830033us-gaap:CommonStockMember2023-03-310001830033pct:PublicWarrantsAndPrivateWarrantsMember2021-03-172021-03-170001830033pct:PublicWarrantMember2023-03-310001830033pct:PrivateWarrantMember2022-03-310001830033pct:PrivateWarrantMember2023-01-012023-03-310001830033pct:PrivateWarrantMember2022-01-012022-03-310001830033pct:SeriesAWarrantsMember2022-03-172022-03-170001830033pct:SeriesAWarrantsMember2022-03-170001830033us-gaap:MeasurementInputOptionVolatilityMemberpct:SeriesAWarrantsMember2023-03-310001830033pct:SeriesAWarrantsMember2023-03-310001830033pct:SeriesAWarrantsMember2023-01-012023-03-310001830033pct:SeriesAWarrantsMember2022-01-012022-03-310001830033us-gaap:WarrantMember2023-01-012023-03-310001830033us-gaap:WarrantMember2022-01-012022-03-310001830033us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001830033us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001830033us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001830033us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001830033us-gaap:PerformanceSharesMember2023-01-012023-03-310001830033us-gaap:PerformanceSharesMember2022-01-012022-03-310001830033pct:ContingentlyIssuableSharesMember2023-01-012023-03-310001830033pct:ContingentlyIssuableSharesMember2022-01-012022-03-310001830033us-gaap:BuildingMember2023-03-310001830033us-gaap:MachineryAndEquipmentMember2023-03-310001830033us-gaap:LeaseholdImprovementsMember2023-03-310001830033us-gaap:FurnitureAndFixturesMember2023-03-310001830033us-gaap:LandImprovementsMember2023-03-310001830033us-gaap:LandMember2023-03-310001830033us-gaap:ConstructionInProgressMember2023-03-310001830033us-gaap:BuildingMember2022-12-310001830033us-gaap:MachineryAndEquipmentMember2022-12-310001830033us-gaap:LeaseholdImprovementsMember2022-12-310001830033us-gaap:FurnitureAndFixturesMember2022-12-310001830033us-gaap:LandImprovementsMember2022-12-310001830033us-gaap:LandMember2022-12-310001830033us-gaap:ConstructionInProgressMember2022-12-310001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:ProctorGambleMember2015-10-16pct:phasepct:employee0001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:ProctorGambleMember2019-04-300001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:ProctorGambleMember2023-03-270001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:ProctorGambleMember2022-12-310001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:ProctorGambleMember2023-03-310001830033pct:ImpactRecyclingLimitedMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2019-11-132019-11-130001830033pct:ImpactRecyclingLimitedMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2020-01-012020-12-310001830033pct:ImpactRecyclingLimitedMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2021-01-012021-12-310001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:TotalPetrochemicalsRefiningSANVMember2020-06-232020-06-230001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:NestleLtdMember2018-12-130001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:NestleLtdMember2018-12-132018-12-130001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:NestleLtdMember2023-03-310001830033us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMemberpct:NestleLtdMember2022-12-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:MunicipalBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel1Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033pct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel1Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel2Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033pct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2023-03-310001830033us-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2023-03-310001830033us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2022-12-310001830033us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2022-12-310001830033us-gaap:FairValueMeasurementsRecurringMemberpct:SeriesAWarrantsMember2022-12-310001830033us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Memberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMemberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMemberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMemberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMemberpct:PrivateWarrantMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberpct:PrivateWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberpct:PrivateWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberpct:PrivateWarrantMember2023-01-012023-03-310001830033us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:MeasurementInputExpectedDividendRateMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMemberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputOptionVolatilityMemberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMemberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMemberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMemberus-gaap:FairValueMeasurementsRecurringMemberpct:RTIWarrantMember2022-12-310001830033pct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel3Memberpct:RTIWarrantMember2022-12-310001830033us-gaap:FairValueInputsLevel3Memberpct:RTIWarrantMember2023-01-012023-03-310001830033us-gaap:FairValueInputsLevel3Memberpct:RTIWarrantMember2023-03-310001830033us-gaap:FairValueInputsLevel2Memberpct:SeriesAWarrantsMember2022-03-170001830033us-gaap:CommercialPaperMember2023-03-310001830033us-gaap:CorporateBondSecuritiesMember2023-03-310001830033us-gaap:MunicipalBondsMember2023-03-310001830033us-gaap:CommercialPaperMember2022-12-310001830033us-gaap:CorporateBondSecuritiesMember2022-12-310001830033us-gaap:MunicipalBondsMember2022-12-310001830033us-gaap:SuretyBondMember2023-03-140001830033us-gaap:SuretyBondMember2023-03-142023-03-1400018300332021-05-11pct:classAction00018300332022-08-2400018300332023-01-31iso4217:EUR0001830033pct:SecuredOvernightFinancingRateSOFRMemberus-gaap:SubsequentEventMemberpct:PurePlasticTermLoanFacilityMember2023-05-082023-05-080001830033us-gaap:SubsequentEventMemberpct:PurePlasticTermLoanFacilityMember2023-05-082023-05-080001830033us-gaap:SubsequentEventMemberpct:PurePlasticTermLoanFacilityMemberpct:DebtInstrumentPrepaymentTermsPeriodOneMember2023-05-082023-05-080001830033us-gaap:SubsequentEventMemberpct:PurePlasticTermLoanFacilityMemberpct:DebtInstrumentPrepaymentTermsPeriodTwoMember2023-05-082023-05-080001830033us-gaap:SubsequentEventMember2023-05-052023-05-050001830033us-gaap:SubsequentEventMemberpct:SylebraAmendmentMember2023-05-08

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For transition period from         to
Commission File Number 001-40234
PureCycle_Logo_hrz_RGB.jpg
PureCycle Technologies, Inc.
(Exact name of registrant as specified in its charter)
State86-2293091
Delaware
(I.R.S. Employer
Identification Number)
5950 Hazeltine National Drive, Suite 300
Orlando, Florida 32822
(877) 648-3565
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolsName of each exchange on which registered
Common Stock, par value $0.001 per sharePCTThe Nasdaq Stock Market LLC
Warrants, each exercisable for one share of common stock, $0.001 par value per share, at an exercise price of $11.50 per sharePCTTWThe Nasdaq Stock Market LLC
Units, each consisting of one share of common stock, $0.001 par value per share, and three quarters of one warrantPCTTUThe Nasdaq Stock Market LLC
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes No ☒
As of May 5, 2023, there were approximately 163,670,396 shares of the registrant's common stock, par value $0.001 per share, outstanding.
1

PureCycle Technologies, Inc.
QUARTERLY REPORT on FORM 10-Q
TABLE OF CONTENTS


Page
PART I - Financial Information
Item 1. Financial Statements
Condensed Consolidated Balance Sheets as of March 31, 2023 (Unaudited) and December 31, 2022
Unaudited Condensed Consolidated Statements of Comprehensive Loss for the Three months ended March 31, 2023 and 2022
Unaudited Condensed Consolidated Statements of Stockholder’s Equity for the Three months ended March 31, 2023 and 2022
Unaudited Condensed Consolidated Statements of Cash Flows for the Three months ended March 31, 2023 and 2022
2

PureCycle Technologies, Inc.
PART I - FINANCIAL INFORMATION
CAUTIONARY STATEMENT ON FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements about the financial condition, results of operations, earnings outlook and prospects of PureCycle Technologies, Inc. (“PCT”). Forward-looking statements generally relate to future events or PCT’s future financial or operating performance and may refer to projections and forecasts. Forward-looking statements are typically identified by words such as “plan,” “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict,” “should,” “would” and other similar words and expressions (or the negative versions of such words or expressions), but the absence of these words does not mean that a statement is not forward-looking.
The forward-looking statements are based on the current expectations of the management of PCT and are inherently subject to uncertainties and changes in circumstances and their potential effects and speak only as of the date of this Quarterly Report on Form 10-Q. There can be no assurance that future developments will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described in the section of PCT’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022 (the “Annual Report on Form 10-K”) entitled “Risk Factors,” those discussed and identified in public filings made with the U.S. Securities and Exchange Commission (the “SEC”) by PCT and the following:
•    PCT's ability to obtain funding for its operations and future growth and to continue as a going concern;
•    PCT's ability to meet, and to continue to meet, applicable regulatory requirements for the use of PCT’s UPR resin (as defined below) in food grade applications (including in the United States, Europe and other future international locations);
•    PCT's ability to comply on an ongoing basis with the numerous regulatory requirements applicable to the UPR resin and PCT’s facilities (including in the United States, Europe and other future international locations);
•    Expectations and changes regarding PCT’s strategies and future financial performance, including its future business plans, expansion plans or objectives, prospective performance and opportunities and competitors, revenues, products and services, pricing, operating expenses, market trends, liquidity, cash flows and uses of cash, capital expenditures, and PCT’s ability to invest in growth initiatives;
•    PCT’s ability to complete and commission its first commercial-scale recycling facility in Lawrence County, Ohio (the “Ironton Facility”) in a timely and cost-effective manner;
•    PureCycle’s ability to complete the necessary funding with respect to, and complete the construction of, (i) its first U.S. multi-line facility, located in Augusta, Georgia (the “Augusta Facility”); (ii) its first commercial-scale European plant located in Antwerp, Belgium and (iii) its first commercial-scale Asian plant located in Ulsan, South Korea, in a timely and cost-effective manner;
•    PCT’s ability to sort and process polypropylene plastic waste at its plastic waste prep (“Feed PreP”) facilities;
•    PCT’s ability to maintain exclusivity under the Procter & Gamble Company (“P&G”) license (as described below);
•    the implementation, market acceptance and success of PCT’s business model and growth strategy;
•    the success or profitability of PCT’s offtake arrangements;
•    the ability to source feedstock with a high polypropylene content at a reasonable cost;
3

PureCycle Technologies, Inc.
PART I - FINANCIAL INFORMATION — CONTINUED
•    PCT’s future capital requirements and sources and uses of cash;
•    developments and projections relating to PCT’s competitors and industry;
•    the outcome of any legal or regulatory proceedings to which PCT is, or may become, a party including the securities class action case;
•    geopolitical risk and changes in applicable laws or regulations;
•    the possibility that PCT may be adversely affected by other economic, business, and/or competitive factors, including rising interest rates, availability of capital, economic cycles, and other macro-economic impacts;
•    turnover or increases in employees and employee-related costs;
•    changes in the prices and availability of labor (including labor shortages), transportation and materials, including significant inflation, supply chain conditions and its related impact on energy and raw materials, and PureCycle’s ability to obtain them in a timely and cost-effective manner;
•    any business disruptions due to political or economic instability, pandemics, armed hostilities (including the ongoing conflict between Russia and Ukraine);
•    the potential impact of climate change on the company, including physical and transition risks, higher regulatory and compliance costs, reputational risks, and availability of capital on attractive terms; and
•    operational risk.

PCT undertakes no obligation to update any forward-looking statements made in this Quarterly Report on Form 10-Q to reflect events or circumstances after the date of this Quarterly Report on Form 10-Q or to reflect new information or the occurrence of unanticipated events, except as required by law.

Should one or more of these risks or uncertainties materialize or should any of the assumptions made prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events.

4

PureCycle Technologies, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS
(Unaudited)
(in thousands except per share data)March 31, 2023December 31, 2022
CURRENT ASSETS
Cash and cash equivalents$38,381 $63,892 
Debt securities available for sale 98,592 
Restricted cash – current68,028 68,850 
Prepaid expenses and other current assets7,375 4,883 
Total current assets113,784 236,217 
Restricted cash – non-current157,466 94,781 
Prepaid expenses and other non-current assets5,657 5,483 
Operating lease right-of-use assets18,939 19,136 
Property, plant and equipment, net579,585 505,719 
TOTAL ASSETS$875,431 $861,336 
LIABILITIES AND STOCKHOLDERS’ EQUITY
CURRENT LIABILITIES
Accounts payable$22,577 $1,667 
Accrued expenses41,902 35,102 
Accrued interest6,127 1,532 
Total current liabilities70,606 38,301 
NON-CURRENT LIABILITIES
Deferred revenue5,000 5,000 
Bonds payable233,778 233,513 
Warrant liability60,718 55,883 
Operating lease right-of-use liabilities16,522 16,620 
Other non-current liabilities1,236 1,136 
TOTAL LIABILITIES$387,860 $350,453 
COMMITMENT AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common shares - $0.001 par value, 250,000 shares authorized; 163,671 and 163,550 shares issued and outstanding as of March 31, 2023 and December 31, 2022
$164 $164 
Additional paid-in capital755,774 753,885 
Accumulated other comprehensive loss (641)
Accumulated deficit(268,367)(242,525)
TOTAL STOCKHOLDERS' EQUITY487,571 510,883 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$875,431 $861,336 
The accompanying notes are an integral part of these financial statements.
5

PureCycle Technologies, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)

Three months ended March 31,
20232022
(in thousands except per share data)
Costs and expenses
Operating costs$8,493 $4,048 
Research and development393 339 
Selling, general and administrative12,935 14,747 
Total operating costs and expenses21,821 19,134 
Interest (income) expense(1,276)444 
Change in fair value of warrants4,835 5,835 
Other expense462 19 
Total other expense4,021 6,298 
Net loss$(25,842)$(25,432)
Loss per share
Basic and diluted$(0.16)$(0.19)
Weighted average common shares
Basic and diluted163,588 133,244 
Other comprehensive loss
Unrealized gain (loss) on debt securities available for sale$641 $(340)
Total comprehensive loss$(25,201)$(25,772)
The accompanying notes are an integral part of these financial statements.
6

PureCycle Technologies, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(Unaudited)
For the three months ended March 31, 2023
Common stock
(in thousands)SharesAmountAdditional paid-in capitalAccumulated other comprehensive lossAccumulated deficitTotal stockholders' equity
Balance, December 31, 2022163,550 $164 $753,885 $(641)$(242,525)$510,883 
Share repurchase(48)— (277)— — (277)
Equity based compensation169  2,166 — — 2,166 
Unrealized gain on available for sale debt securities— — — 641 — 641 
Net loss— — — — (25,842)(25,842)
Balance, March 31, 2023163,671 $164 $755,774 $ $(268,367)$487,571 
For the three months ended March 31, 2022
Common stock
(in thousands)SharesAmountAdditional paid-in capitalAccumulated other comprehensive lossAccumulated deficitTotal stockholders' equity
Balance, December 31, 2021127,647 $128 $539,423 $(237)$(157,779)$381,535 
Issuance of common stock35,714 35 205,261 — — $205,296 
Share repurchase(130)— (1,049)— — $(1,049)
Equity based compensation3  3,171 — — $3,171 
Unrealized loss on available for sale debt securities— — — (340)— $(340)
Net loss— — — — (25,432)$(25,432)
Balance, March 31, 2022163,234 163 746,806 (577)(183,211)563,181 
The accompanying notes are an integral part of these financial statements.
7

PureCycle Technologies, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
Three months ended March 31,
(in thousands)20232022
Cash flows from operating activities
Net loss$(25,842)$(25,432)
Adjustments to reconcile net loss to net cash used in operating activities

Equity-based compensation2,166 3,171 
Fair value change of warrants4,835 5,835 
Depreciation expense1,294 818 
Amortization of debt issuance costs and debt discounts265 244 
(Accretion) amortization of (discount) premium on debt securities(138)146 
Operating lease amortization expense926 287 
Changes in operating assets and liabilities
Prepaid expenses and other current assets(1,148)(479)
Prepaid expenses and other non-current assets(174)11 
Accounts payable1,218 747 
Accrued expenses2,116 (2,503)
Accrued interest324 324 
Operating right-of-use liabilities(597)(93)
Net cash used in operating activities$(14,755)$(16,924)
Cash flows from investing activities
Construction of plant(46,632)(52,177)
Purchase of debt securities, available for sale (98,070)
Sale and maturity of debt securities, available for sale99,371 45,189 
Net cash provided by (used in) investing activities$52,739 $(105,058)
Cash flows from financing activities
Debt issuance costs(1,344) 
Payments to repurchase shares(277)(1,049)
Other payments for financing activities(11)(10)
Proceeds from issuance of common stock 206,071 
Proceeds from issuance of warrants 43,929 
Common stock issuance costs (775)
Net cash (used in) provided by financing activities$(1,632)$248,166 
Net increase in cash and restricted cash36,352 126,184 
Cash and restricted cash, beginning of period227,523 263,858 
Cash and restricted cash, end of period$263,875 $390,042 
Supplemental disclosure of cash flow information
Non-cash investing activities
Additions to property, plant, and equipment in accrued expenses$30,809 $13,918 
Additions to property, plant, and equipment in accounts payable$20,509 $329 
Additions to property, plant, and equipment in accrued interest$4,271 $4,271 
The accompanying notes are an integral part of these financial statements.
8

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)

NOTE 1 - ORGANIZATION
Formation and Organization
PureCycle Technologies, Inc. (“PCT” or “Company”) is a Florida-based corporation focused on commercializing a patented purification recycling technology (the “Technology”), originally developed by The Procter & Gamble Company (“P&G”), for restoring waste polypropylene into resin, called ultra-pure recycled (“UPR”) resin, which has nearly identical properties and applicability for reuse as virgin polypropylene. PCT has a global license for the Technology from P&G. PCT’s goal is to create an important new segment of the global polypropylene market that will assist multinational entities in meeting their sustainability goals, providing consumers with polypropylene-based products that are sustainable, and reducing overall polypropylene waste in the world’s landfills and oceans.
Business Combination
On March 17, 2021, PureCycle consummated the previously announced business combination (“Business Combination”) by and among Roth CH Acquisition I Co., a Delaware corporation (“ROCH”), Roth CH Acquisition I Co. Parent Corp., a Delaware corporation and wholly owned direct subsidiary of ROCH (“ParentCo”), Roth CH Merger Sub LLC, a Delaware limited liability company and wholly owned direct subsidiary of Parent Co, Roth CH Merger Sub Corp., a Delaware corporation and wholly owned direct subsidiary of ParentCo and PureCycle Technologies LLC (“PCT LLC” or “Legacy PCT”) pursuant to the Agreement and Plan of Merger dated as of November 16, 2020, as amended from time to time (the “Merger Agreement”).
Upon the completion of the Business Combination and the other transactions contemplated by the Merger Agreement (the “Transactions”, and such completion, the “Closing”), ROCH changed its name to PureCycle Technologies Holdings Corp. and became a wholly owned direct subsidiary of ParentCo, PCT LLC became a wholly owned direct subsidiary of PureCycle Technologies Holdings Corp. and a wholly owned indirect subsidiary of ParentCo, and ParentCo changed its name to PureCycle Technologies, Inc. The Company’s common stock, units and warrants are now listed on the Nasdaq Capital Market (“NASDAQ”) under the symbols “PCT,” “PCTTU” and “PCTTW,” respectively.
Legacy PCT unitholders will be issued up to 4.0 million additional shares of the Company’s common stock if certain conditions are met (“the Earnout”). The Legacy PCT unitholders will be entitled to 2.0 million shares if after 1 year after the Closing and prior to or as of the third anniversary of the Closing, the closing price of the common stock is greater than or equal to $18.00 over any 20 trading days within any 30-trading day period. The Legacy PCT unitholders will be entitled to 2.0 million shares upon the Ironton Facility becoming operational, as certified by Leidos Engineering, LLC (“Leidos”), an independent engineering firm, in accordance with criteria established in agreements in connection with construction of the plant.
Unless the context otherwise requires, “Registrant,” “PureCycle,” “Company,” “PCT,” “we,” “us,” and “our” refer to PureCycle Technologies, Inc., and its subsidiaries at and after the Closing and give effect to the Closing. “Legacy PCT”, “ROCH” and “ParentCo” refer to PureCycle Technologies LLC, ROCH and ParentCo, respectively, prior to the Closing.
Private Placement Offering
On March 7, 2022, the Company entered into subscription agreements (the “Subscription Agreements”) with certain investors (the “2022 PIPE Investors”), pursuant to which the Company agreed to sell to the Investors, in a private placement, shares of the Company’s common stock, par value $0.001 per share, and Series A warrants to purchase shares of Common Stock (the “Series A Warrants”) at a price of $7.00 per share of Common Stock and one-half (1/2) of one Series A Warrant (the “2022 PIPE Offering”).
On March 17, 2022, the Company closed the 2022 PIPE Offering and issued to the 2022 PIPE Investors an aggregate of 35,714,272 shares of Common Stock and Series A Warrants to purchase an aggregate of 17,857,136 shares of Common Stock. The Company received approximately $250.0 million in gross proceeds from the 2022
9

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
PIPE Offering. The Company incurred approximately $0.8 million of expenses primarily related to advisory fees in conjunction with the 2022 PIPE Offering.
Refer to Note 6 – Warrants for further information.
Basis of Presentation
The accompanying condensed consolidated interim financial statements include the accounts of the Company. The condensed consolidated interim financial statements are presented in U.S. Dollars. Certain information in footnote disclosures normally included in annual financial statements was condensed or omitted for the interim periods presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) and accounting principles generally accepted in the United States of America (“U.S. GAAP”). Intercompany balances and transactions were eliminated upon consolidation. The results of operations for the three months ended March 31, 2023 are not necessarily indicative of the results to be expected for the entire year ending December 31, 2023. The accompanying condensed consolidated interim financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of management, necessary to present a fair statement of the results for the interim periods presented.
Liquidity and Going Concern
The accompanying consolidated financial statements have been prepared assuming that PCT will continue as a going concern; however, the conditions described below raise substantial doubt about PCT’s ability to do so, which management believes has been alleviated through its plans to mitigate these conditions and obtain additional unrestricted liquidity.
The Company has sustained recurring losses and negative cash flows from operations since its inception. As reflected in the accompanying consolidated financial statements, the Company has not yet begun commercial operations and does not have any sources of revenue. The following is a summary of the components of our current liquidity (in thousands):

As of
March 31, 2023December 31, 2022
Cash and cash equivalents$38,381 $63,892 
Debt securities available for sale$ $98,592 
Unrestricted liquidity$38,381 $162,484 
Less: Other Ironton set-aside$ $54,560 
Available unrestricted liquidity$38,381 $107,924 
Restricted Cash (current and non-current)$225,494 $163,631 
Working capital$43,178 $197,916 
Accumulated deficit$(268,367)$(242,525)
For the three months ended
March 31, 2023March 31, 2022
Net loss$(25,842)$(25,432)
As of March 31, 2023, PCT had $38.4 million of Available Unrestricted Liquidity. On March 15, 2023, PCT entered into a $150.0 million revolving credit facility (the “Revolving Credit Facility”). Borrowings under the Revolving Credit Agreement may be used for working capital, capital expenditures and other general corporate purposes and satisfies the financing obligation imposed upon PCT by the Limited Waiver (as defined below) – refer to Note 3 –
10

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
Notes Payable and Debt Instruments for additional information. Also in March 2023, PCT, pursuant to a Limited Waiver agreement with the Revenue Bondholders, agreed to fund additional reserves for capitalized interest of approximately $12.3 million; contribute $25.2 million to a construction project account to pay for additional Ironton facility construction costs and to transfer $50.0 million to a Revenue Bondholder escrow account (previously reflected as Other Ironton set-aside above). Additionally, the Revenue Bondholders agreed to release $13.2 million from the Trustee account for the Revenue Bonds for use as part of the remaining investment in 2023 to complete the Ironton Facility. This resulted in a net transfer of cash from unrestricted to restricted cash of $74.3 million.
As of March 31, 2023, PCT anticipates that the remaining investment to complete the Ironton Facility could range from $26.0 million up to $51.0 million, of which $25.2 million is set aside in restricted cash. This range is dependent upon various contract contingencies and their ultimate resolution. PCT expects to successfully negotiate at least some of these contingencies, which would reduce the remaining 2023 investment to the lower end of the range.

PCT also has other capital commitments of approximately $21.2 million related to long-lead equipment and pre-construction work for the Augusta Facility and $39.9 million for equipment and leases related to future Feed PreP and purification facilities. There are also ongoing monthly costs associated with managing the company and preparing the Ironton Facility to become operational.
PCT believes that its current level of Unrestricted Available Liquidity is not sufficient to fund operations, outstanding commitments, and further its future growth plans. The conditions described above raise substantial doubt regarding PCT’s ability to continue as a going concern for a period of at least one year from the date of issuance of the condensed consolidated interim financial statements included in this Quarterly Report on Form 10-Q.
In an effort to alleviate these conditions, on May 8, 2023, PureCycle Technologies, Inc. (the “Company) entered into a $40 million term loan facility (the “Term Loan Facility”) pursuant to a Credit Agreement (the “Term Loan Credit Agreement”) dated as of May 8, 2023, among the Company, as the borrower, PureCycle Technologies Holdings Corp., PureCycle Technologies, LLC and the subsidiaries of the Company as are or may from time to time become parties to the Term Loan Facility as guarantors (the “Guarantors”) and Pure Plastic LLC (as a “Lender,” “Administrative Agent,” and “Security Agent”), which matures on December 31, 2025. Affiliates of the Lender are greater than 5% beneficial owners of the Company. Borrowings under the Term Loan Credit Agreement may be used to repay indebtedness for borrowed money of the Company, to pay fees and expenses associated with the Term Loan Credit Agreement and the other loan documents and for general corporate purposes not in contravention of any law or of any loan document. Refer to Note 16 – Subsequent Events for additional information.
In addition, on May 8, 2023, the Company, through PureCycle PreP LLC, an indirect wholly-owned subsidiary of the Company, entered into a Master Lease Agreement (the “Master Lease Agreement”) and Equipment Procurement Agreement (the “Equipment Agreement”) with CSC Leasing Co. (“CSC”). Under the terms of the Equipment Agreement, CSC has agreed to finance, acquire and/or purchase certain equipment (the “Equipment”) from third-party vendors and/or manufacturers (each, a “Vendor”), so that CSC may lease the Equipment to the Company pursuant to the terms and conditions of the Master Lease Agreement. The Company intends to lease assorted equipment in the amount of up to $22.0 million in connection with these agreements. Refer to Note 16 – Subsequent Events for additional information.
After considering managements plans to mitigate these conditions, including the addition of up to $62 million of available unrestricted liquidity provided by through the agreements discussed above, PCT believes this substantial doubt has been alleviated and it has sufficient liquidity to continue as a going concern for the next twelve months.
PCT’s future capital requirements will depend on many factors, including actual construction costs for the Ironton Facility, the funding mechanism and construction schedule of the Augusta Facility and other anticipated facilities outside the United States, build-out of multiple Feed PreP facilities, funding needs to support other business opportunities, funding for general corporate purposes, and other challenges or unforeseen circumstances. As a pre-revenue operating company, PCT continually reviews its cash outlays, pace of hiring, professional services and other spend, and capital commitments to proactively manage those needs in tandem with our available unrestricted liquidity balance. For future growth and investment, PCT expects to seek additional debt or equity financing from outside sources, which it may not be able to raise on terms favorable to PCT, or at all. If PCT is unable to raise additional debt or sell additional equity when desired, or if PCT is unable to manage its cash outflows, PCT’s
11

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
business, financial condition, and results of operations would be adversely affected. In addition, any financing arrangement may have potentially adverse effects on PCT and/or its stockholders. Debt financing (if available and undertaken) will increase expenses, must be repaid regardless of operating results and may involve restrictions limiting PCT’s operating flexibility. If PCT consummates an equity financing to raise additional funds, the percentage ownership of its existing stockholders will be reduced, and the new equity securities may have rights, preferences or privileges senior to those of the current holders of PCT’s common stock.
NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Going Concern
Refer to Note 1 – Organization for further discussion.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original maturity of three months or less at date of inception to be cash and cash equivalents. The Company’s cash and cash equivalents balance represents cash and money market funds deposited with financial institutions. These balances may exceed federally insured limits; however, the Company believes the risk of loss is low. Actively traded money market funds are measured at their net asset value (“NAV”) and classified as Level 1.
Restricted Cash
Proceeds from the issuance of revenue bonds are restricted for use in construction of the production facility. Amounts required by the Limited Waiver (refer to Note 3 – Notes Payable and Debt Instruments) were also placed in restricted cash for various future uses. Cash pledged as collateral for leased properties is also deemed restricted and included within this definition. Restricted cash that is expected to be spent or released from restriction within twelve months is classified as current on the consolidated balance sheet. Restricted cash that is expected to be spent or released from restriction after twelve months is classified as non-current on the consolidated balance sheet.
Investments
The Company accounts for its investment in Debt Securities in accordance with ASC 320, Investments – Debt Securities. The fair value for fixed-rate debt securities is based on quoted market prices for the same or similar debt instruments and is classified as Level 2. The Company had no investments holdings as of March 31, 2023. All investment holdings as of December 31, 2022 were classified as Available for Sale. The Company classifies its Debt Securities investments as current assets as they are highly liquid and the related funds are available for use in current operations.

Income Taxes
To calculate the interim tax provision, at the end of each interim period the Company estimates the annual effective tax rate and applies that to its ordinary quarterly earnings. The effect of changes in the enacted tax laws or rates is recognized in the interim period in which the change occurs. The computation of the annual estimated effective tax rate at each interim period requires certain estimates and judgments including, but not limited to, the expected operating income for the year, projections of the proportion of income earned and taxed in other jurisdictions, permanent differences between book and tax amounts, and the likelihood of recovering deferred tax assets generated in the current year. The accounting estimates used to compute the provision for income taxes may change as new events occur, additional information is obtained, or the tax environment changes.
Warrants
The Company evaluates all of its financial instruments, including issued warrants, to determine if such instruments are liability classified, pursuant to ASC 480 - Distinguishing Liabilities from Equity (“ASC 480”) or derivatives or contain features that qualify as embedded derivatives pursuant to ASC 815 – Derivatives and Hedging (“ASC 815”). The classification of instruments, including whether such instruments should be recorded as liabilities or as equity, is
12

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
re-assessed at the end of each reporting period. Issuance costs incurred with the Business Combination that are attributable to liability classified warrants are expensed as incurred.
Recently Issued Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments (“ASU 2016-13”), which, together with subsequent amendments, amends the requirement on the measurement and recognition of expected credit losses for financial assets held. The Company adopted the ASU during the first quarter of 2023 using a prospective approach. The adoption of the ASU did not have a material impact on the Company’s condensed consolidated financial statements.
NOTE 3 – NOTES PAYABLE AND DEBT INSTRUMENTS
Long-term debt consists of the following at March 31, 2023 and December 31, 2022:
March 31, 2023December 31, 2022
Revenue Bonds$249,550 $249,550 
Less: Original issue discount and debt issuance costs classified as a reduction to long-term debt(15,772)(16,037)
Bonds payable - long-term$233,778 $233,513 
Revenue Bonds
On October 7, 2020, the Southern Ohio Port Authority (“SOPA”) issued certain revenue bonds (“Revenue Bonds”) pursuant to an Indenture of Trust dated as of October 1, 2020 (as amended, restated, supplemented or otherwise modified from time to time, the “Indenture”), between SOPA and UMB Bank, N.A., as Trustee (“Trustee”), and loaned the proceeds from their sale to PureCycle: Ohio LLC (“PCO”), an Ohio limited liability company and indirect wholly-owned subsidiary of PCT, pursuant to a Loan Agreement dated as of October 1, 2020, between SOPA and PCO (as amended, restated, supplemented or otherwise modified from time to time, the “Loan Agreement”), to be used to (i) acquire, construct and equip the Ironton Facility (referred to within the Loan Agreement as the “Ohio Phase II Facility” and, together with the FEU (referred to within the Loan Agreement as the “Phase I Facility”), the “Project”); (ii) fund a debt service reserve fund for the Series 2020A Bonds; (iii) finance capitalized interest; and (iv) pay the costs of issuing the Revenue Bonds. The Revenue Bonds were offered in three series, including (i) Exempt Facility Revenue Bonds (PureCycle Project), Tax-Exempt Series 2020A (“Series 2020A Bonds”); (ii) Subordinate Exempt Facility Revenue Bonds (PureCycle Project), Tax-Exempt Series 2020B (“Series 2020B Bonds”); and (iii) Subordinated Exempt Facility Revenue Bonds (PureCycle Project), Taxable Series 2020C (“Series 2020C Bonds”), each series in the aggregate principal amount, bearing interest and maturing as shown in the table below. The Series 2020A Bonds were issued at a total discount of $5.5 million. The discount is amortized over the term of the Revenue Bonds using the effective interest method. The purchase price of the Revenue Bonds was paid and immediately available to SOPA on October 7, 2020, the date of delivery of the Revenue Bonds to their original purchaser. PureCycle is not a direct obligor on the Revenue Bonds and is not a party to the Loan Agreement or the Indenture pursuant to which the Revenue Bonds have been issued. Legacy PCT has executed a guaranty of completion dated as of October 7, 2020 (“Guaranty”), with respect to the full and complete performance by PCO of PCO’s obligations with respect to construction and completion of the Project, including construction by the Completion Date, free and clear of any liens (other than permitted liens), and the payment of all Project costs incurred prior to completion of the Project, and all claims, liabilities, losses and damages owed by PCO to each counterparty under the Project Documents (as such terms are defined in the Indenture). In addition, pursuant to the Guaranty, PCT LLC is obligated to fund and maintain a liquidity reserve for the Project during the term of the Guaranty in the amount of $50.0 million to be held in an escrow account with U.S. Bank National Association, as escrow agent (“Liquidity Reserve”). Pursuant to the terms of the Loan Agreement PCO executed promissory notes
13

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
in the principal amounts of each maturity (or interest rate within a maturity), aggregating the principal amount of each series of Revenue Bonds, in favor of SOPA, which were assigned to the Trustee on October 7, 2020.
(in thousands)
Bond Series Term Principal Amount Interest Rate Maturity Date
2020A A1 $12,370.00 6.25 %December 1, 2025
2020A A2 $38,700.00 6.50 %December 1, 2030
2020A A3 $168,480.00 7.00 %December 1, 2042
2020B B1 $10,000.00 10.00 %December 1, 2025
2020B B2 $10,000.00 10.00 %December 1, 2027
2020C C1 $10,000.00 13.00 %December 1, 2027
The proceeds of the Revenue Bonds and certain equity contributions have been placed in various trust funds and non-interest-bearing accounts established and administered by the Trustee under the Indenture. Before each disbursement of amounts in the Project Fund held by the Trustee under the Indenture, PCO is required to submit to the Trustee a requisition for funds to be disbursed outlining the specified purpose of the disbursement and substantiating the expenditure. In addition, 100% of revenue attributable to the production of the Ironton Facility must be deposited into an operating revenue escrow fund held by U.S. Bank Trust Company, National Association, as escrow agent. Funds in the trust accounts and operating revenue escrow fund will be disbursed by the Trustee when certain conditions are met, and will be used to pay costs and expenditures related to the development and operation of the Ironton Facility, make required interest and principal payments (including sinking fund redemption amounts) and pay any premium, in certain circumstances required under the Indenture, to redeem the Revenue Bonds.
As conditions for closing of the Revenue Bonds, Legacy PCT contributed $60.0 million in equity at closing and PureCycle and certain affiliates contributed an additional $40.0 million in equity upon the Closing of the Business Combination. PureCycle provided the Liquidity Reserve for construction of the Ironton Facility of $50.0 million and deposited that amount upon the Closing of the Business Combination. In addition, PureCycle must maintain $100.0 million of cash on its balance sheet as of January 31, 2022, including the Liquidity Reserve. The Company met these requirements and continues to maintain that cash balance at March 31, 2023.
The Revenue Bonds are recorded within Bonds payable in the condensed consolidated balance sheet. The Company incurred $4.8 million of interest cost during each of the three months ended March 31, 2023 and March 31, 2022, respectively. As the Revenue Bond proceeds are being used to construct the Company’s property, plant and equipment, the interest costs related to the tax-exempt portion of the Revenue Bonds have been capitalized within Property, Plant and Equipment. The Company capitalized $4.3 million of interest cost during each of the three months ended March 31, 2023 and March 31, 2022, respectively. As of March 31, 2023 the fair value of the Revenue Bonds was $209.5 million, which was determined using inputs characteristic of a Level 2 fair value measurement. Although the Company has determined the estimated fair value using available market information and commonly accepted valuation methodologies, considerable judgement is required in interpreting the information and in developing the estimated fair value. Therefore, this estimate is not necessarily indicative of the amounts that the Company, or holders of the instruments, could realize in a current market exchange.
In connection with its obligations under that certain Security Agreement dated as of October 7, 2020, between PCO, as debtor, and the Trustee, as secured party, entered into when the Revenue Bonds were issued (the “Security Agreement”), PCO must deliver consent and agreements (“Consents”) to the Trustee with respect to each agreement entered into in connection with the Project, each of which agreements is required under the Loan Agreement to be assigned to the Trustee. The forms of the Consents relating to a certain feedstock supply agreement from one supplier of feedstock to the Project (the “Supplier”) and from two purchasers of offtake from the Project (“Offtaker 2” and “Offtaker 3” and together with the Supplier, the “Counterparties”) delivered to the Trustee contained terms inconsistent with the form of the Consent required under the Security Agreement. On May 11, 2021, the Guaranty was amended and restated in an amended and restated guaranty of completion (the “ARG”) executed by PureCycle and delivered to the Trustee, which broadens the purposes for which draws by the Trustee on the Liquidity Reserve may be utilized, extends the period during which the Liquidity Reserve must be maintained, includes conditions that would permit a reduction in the amount of the Liquidity Reserve required to be maintained
14

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
by PureCycle, and includes conditions precedent to the elimination of the requirement that PureCycle replenish the Liquidity Reserve and to the termination of the ARG and the escrow agreement under which the Liquidity Reserve is held by the escrow agent (the “Escrow Agreement”), upon which termination, the balance of the Liquidity Reserve will be returned to PureCycle. So long as there are any Series 2020A Bonds outstanding under the Indenture, the ARG and the Escrow Agreement will remain in place upon the conditions stated in the ARG. The terms of the ARG are summarized as follows: The Liquidity Reserve shall be maintained in the amount of $50.0 million, subject to replenishment by PureCycle until certain conditions stated in the ARG relating to the following have been met: (i) the completion of construction and acquisition of the Project, (ii) the payment of all Project costs, and (iii) the replacement of the assigned agreements of the Counterparties underlying the Consents which have expired or terminated, with one or more agreements between counterparties and PCO upon terms at least as favorable to PCO as the expired or terminated agreements of the Counterparties, (a) for which a Consent that conforms to the form of Consent required by the Security Agreement is executed by the counterparties and provided to the Trustee, (b) which, in the case of supply of feedstock to the Project, provide in the aggregate for the supply of at least the minimum and maximum volumes of feedstock meeting substantially similar feedstock specifications as the Supplier had committed to supply, and (c) which, in the case of purchase of offtake from the Project, provide in the aggregate for the purchase of the minimum and maximum volumes of offtake from the Project meeting substantially similar specifications as Offtaker 2 and Offtaker 3 had committed to purchase from PCO. When the conditions stated in (i), (ii) and (iii) above have been satisfied but so long as there are Series 2020A Bonds outstanding under the Indenture, the Escrow Agreement shall remain in place but the Liquidity Reserve amount shall be reduced to $25.0 million and PureCycle shall no longer be required to replenish the amount of the reduced Liquidity Reserve if and when disbursements are made therefrom. If the conditions of (i) and (ii) have been met but only a portion of the feedstock and offtake contracted for by the Counterparties, respectively, has been replaced under replacement agreements as aforesaid in (iii) above, then the Liquidity Reserve amount may be reduced only by the applicable proportion of the amounts stated in the ARG which evidence the intent of the parties of the amount of value representing the supply or offtake of the agreements of the Counterparties. When the conditions precedent of (i), (ii), and (iii) have been satisfied and there are no longer any Series 2020A Bonds then outstanding, then PureCycle shall have no obligation to maintain the reduced Liquidity Reserve, the ARG and the Escrow Agreement shall terminate and the balance on deposit in the Liquidity Reserve escrow fund held by the escrow agent shall be returned to PureCycle.
As long as any Series 2020A Bonds remain outstanding under the Indenture, upon the occurrence of an Event of Default under the Loan Agreement or Indenture, if the Trustee takes control of the Liquidity Reserve held by the escrow agent, such funds may be used for any purpose, including the payment of debt service on the Series 2020A Bonds, as may be determined by the Trustee or directed by a majority of the holders of the Series 2020A Bonds then outstanding.
On March 15, 2023, PCT LLC, PCTO Holdco LLC, a Delaware limited liability company and indirect wholly-owned subsidiary of PCT LLC (the pledgor under an Equity Pledge and Security Agreement (as defined in the Indenture), pursuant to which the pledgor pledged certain interests to secure obligations of PCO under various Financing Documents (as defined in the Indenture) relating to the Revenue Bonds) and PCO (collectively, the “Company Parties”) and SOPA and the Trustee entered into a Limited Waiver and First Supplemental Indenture (the “Limited Waiver”), supplementing the Indenture and amending the Loan Agreement and the ARG, and pursuant to which the majority holders of the Series 2020A Bonds consented to the Limited Waiver, based on stated conditions, of a Specified Event of Default (as defined below) under the Indenture and the Loan Agreement.
Under the terms of the Loan Agreement, PCO was required to cause the Ironton Facility to be completed by December 1, 2022. The Ironton Facility was not completed by that date due to a variety of challenges resulting from, among other things, the COVID-19 outbreak, the ongoing military conflict between Russia and Ukraine, and certain U.S. weather-related events (the “Specified Event of Default”).
Subject to the following conditions, the Specified Event of Default is waived in exchange for PCO’s agreement to meet certain milestones toward completing the Ironton Facility, to deposit additional equity aggregating approximately $87.3 million with the Trustee for various purposes and to make certain other representations and warranties; provided, however, that any failure to comply with the terms of the Limited Waiver shall be an immediate Event of Default under the Indenture and Loan Agreement, which will be deemed to have occurred on January 2, 2023 with respect to any requirements to pay accrued and unpaid interest at the Default Rate (as defined in the Indenture).
15

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
PCO has agreed to, among other things, achieve the following milestones (together, the “Milestones”): (i) closure by it or its direct or indirect parent entity of a financing transaction by March 31, 2023 that provides at least $150.0 million of working capital which may be used to support the Ironton Facility (which milestone was satisfied by the closing of the Revolving Credit Facility); (ii) mechanical completion of the Ironton Facility by June 30, 2023; (iii) meet certain targeted production and performance targets during 2023; (iv) completion of the Ironton Facility by December 31, 2023; and (v) meet certain Ironton Facility pellet production targets by January 31, 2024 up to the Ironton Facility’s nameplate production capacity of 107 million pounds per year.
The additional approximately $87.3 million of equity deposited with the Trustee is comprised of: (i) a deposit of $50 million in an account controlled by the Trustee; (ii) a deposit of approximately $25 million in the Equity Account of the Project Fund (as such terms are used in the Indenture) to fund remaining construction costs; (iii) an aggregate deposit of approximately $12.3 million into the Capitalized Interest Accounts (as defined in the Indenture) for the Series 2020A Bonds, Series 2020B Bonds and Series 2020C Bonds to pay capitalized interest on the Revenue Bonds through June 30, 2024. The Limited Waiver also requires that the Liquidity Reserve of approximately $50 million remain in the Liquidity Reserve Escrow Fund (as defined in the Indenture) for a period beyond the completion date of the Ironton Facility until certain production requirements have been met, and only thereafter may the balance in that fund be reduced based on certain conditions to $25 million, which must remain therein as long as Series 2020A Bonds remain outstanding. The $50 million deposit described above, along with the $50 million remaining in the Liquidity Reserve Escrow Fund, may satisfy the minimum cash requirement of the ARG of $100 million. The Trustee also released $13.2 million from the Project Fund held under the Indenture for use as part of the remaining investment in 2023 to complete the Ironton Facility in accordance with the Limited Waiver.
Sylebra Credit Facility
On March 15, 2023, PCT entered into a $150 million revolving credit facility (the “Revolving Credit Facility”) pursuant to a Credit Agreement (the “Revolving Credit Agreement”) dated as of March 15, 2023, with PureCycle Technologies Holdings Corp. and PureCycle Technologies, LLC (the “Guarantors”), Sylebra Capital Partners Master Fund, LTD, Sylebra Capital Parc Master Fund, and Sylebra Capital Menlo Master Fund (collectively, the “Lenders”), and Madison Pacific Trust Limited (the “Administrative Agent”), which matures on June 30, 2024. The Lenders and their affiliates are greater than 5% beneficial owners of PCT.
Borrowings under the Revolving Credit Agreement may be used for working capital, capital expenditures and other general corporate purposes and satisfies the financing obligation imposed upon PCT by the Limited Waiver.
Amounts outstanding under the Revolving Credit Agreement bear interest at a variable annual rate equal to Term SOFR (as defined in the Revolving Credit Agreement) in effect for such period plus an applicable margin. The applicable margin is equal to (i) 5.00% from the Closing Date through June 30, 2023, (ii) 10.00% from July 1, 2023 through September 30, 2023, (iii) 12.50% from October 1, 2023 through December 31, 2023, (iv) 15.00% from January 1, 2024 through March 31, 2024, and (v) 17.50% thereafter. PCT is also required to pay (i) an up-front fee equal to 0.75% times $150 million—the total aggregate commitment for the Revolving Credit Facility—to the Lenders, payable at closing and (ii) a commitment fee equal to 0.25% per annum based on the actual daily unused amount of the Revolving Credit Facility, payable quarterly. Subject to timely prior written notice and payment of breakage fees, if any, PCT may at any time and from time to time (i) terminate all or any portion of the commitments under the Revolving Credit Agreement and/or (ii) prepay all or any portion of any outstanding borrowings.
The Revolving Credit Agreement contains representations, covenants and events of default that are customary for financing transactions of this nature. Events of default in the Revolving Credit Agreement include, among others: (a) non-payment of principal, interest, fees or other amounts; (b) default of specific covenants; (c) breach of representations and warranties; (d) cross-defaults to other indebtedness in an amount greater than $1 million, subject to certain exceptions; (e) bankruptcy and insolvency proceedings; (f) inability to pay debts or attachment; (g) judgments; and (h) change of control. Upon the occurrence of an event of default, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders (as defined in the Revolving Credit Agreement) terminate the loan commitments, accelerate all loans and exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Revolving Credit Agreement and the other loan documents.
16

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
Amounts outstanding under the Revolving Credit Agreement are guaranteed by the Guarantors, and are secured by a security interest in substantially all of the assets of PCT. Any majority-owned direct or indirect subsidiaries of PCT formed after the closing date of the Revolving Credit Facility will also be required to guaranty the obligations under the Revolving Credit Agreement and grant security interests in substantially all of their respective assets.
There were no funds drawn on the Revolving Credit Facility as of March 31, 2023. The up-front commitment fee and other costs of $1.3 million have been recorded in prepaid expenses and other current assets and will be amortized over the term of the contract.
NOTE 4 - STOCKHOLDERS’ EQUITY
Common Stock
Holders of PCT common stock are entitled to one vote for each share held of record on all matters submitted to a vote of stockholders. The holders do not have cumulative voting rights in the election of directors. Upon the Company’s liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of the Company’s common stock will be entitled to receive pro rata the Company’s remaining assets available for distribution. Holders of the Company’s common stock do not have preemptive, subscription, redemption or conversion rights. All shares of the Company’s common stock are fully paid and non-assessable. The Company is authorized to issue 250.0 million shares of common stock with a par value of $0.001. As of March 31, 2023, and December 31, 2022, 163.67 million and 163.55 million shares are issued and outstanding, respectively.
Preferred Stock
As of March 31, 2023, the Company is authorized to issue 25.0 million shares of preferred stock with a par value of $0.001, of which no shares are issued and outstanding.
NOTE 5 - EQUITY-BASED COMPENSATION
2021 Equity Incentive Plan
On March 17, 2021, our stockholders approved the PureCycle Technologies, Inc. 2021 Equity and Incentive Compensation Plan (the “Plan”).
The Plan provides for the grant of stock options, stock appreciation rights (“SARs”), restricted stock, restricted stock units (“RSUs”), performance shares, performance units, dividend equivalents, and certain other awards. In general, the amount of shares issuable under the Plan will be automatically increased on the first day of each fiscal year, beginning in 2022 and ending in 2031, by an amount equal to the lesser of (a) 3% of the shares of the Company’s common stock outstanding on the last day of the immediately preceding fiscal year and (b) such smaller number of shares as determined by the Board of Directors of the Company.

As of March 31, 2023, approximately 17.0 million shares of common stock are currently authorized for issuance under the Plan, of which approximately 9.1 million shares remain available for issuance under the Plan (assuming maximum performance with respect to the applicable performance goals applicable to the issued Plan awards).
Restricted Stock Agreements
RSUs issued pursuant to the Plan are time-based and vest over the period defined in each individual grant agreement or upon a change of control event as defined in the Plan. The Company recognizes compensation expense for the shares equal to the fair value of the equity-based compensation awards and is recognized on a straight-line basis over the vesting period of such awards. The fair value of the awards is equal to the fair value of the Company’s common stock at the date of grant. The Company has the option to repurchase all vested shares upon a stockholder’s termination of employment or service with the Company.
17

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
A summary of restricted stock activity for the three months ended March 31, 2023 and 2022 is as follows (in thousands except per share data):
Number of RSU'sWeighted average grant date fair valueWeighted average remaining recognition period
Non-vested at December 31, 20212,671 $14.33 3.4
Granted980 7.24 
Vested(438)9.86 
Forfeited(22)17.50 
Non-vested at March 31, 20223,191 $12.75 3.4
Number of RSU'sWeighted average grant date fair valueWeighted average remaining recognition period
Non-vested at December 31, 20222,760 $11.92 2.7
Granted1,075 6.00 
Vested(193)6.96 
Forfeited(34)16.45 
Non-vested at March 31, 20233,608 $10.34 2.9
Equity-based compensation cost is recorded within the selling, general and administrative expenses in the condensed consolidated statements of comprehensive loss, and totaled approximately $2.4 million and $3.4 million for the three months ended March 31, 2023 and 2022, respectively.
Stock Options
The stock options issued pursuant to the Plan are time-based and vest over the period defined in each individual grant agreement or upon a change of control event as defined in the Plan.
The Company recognizes compensation expense for the shares equal to the fair value of the equity-based compensation awards and is recognized on a straight-line basis over the vesting period of such awards. The fair value of the stock is estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions:
March 31, 2023March 31, 2022
Expected annual dividend yield % %
Expected volatility77.3 % %
Risk-free rate of return3.5 % %
Expected option term (years)6.50
The expected term of the shares granted is determined based on the period of time the shares are expected to be outstanding. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The expected volatility was based on the Company’s capital structure and volatility of similar entities referred to as guideline companies. In determining similar entities, the Company considered industry, stage of life cycle, size and financial
18

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
leverage. The dividend yield on the Company’s shares is assumed to be zero as the Company has not historically paid dividends. The fair value of the underlying Company shares was determined using the Company’s closing stock price on the grant date.
A summary of stock option activity for the three months ended March 31, 2023 and 2022 is as follows (in thousands except per share data):
Number of OptionsWeighted Average Exercise PriceWeighted
Average
Remaining
Contractual
Term
(Years)
Balance, December 31, 2021613 $28.90 6.2
Granted  — 
Exercised  — 
Forfeited  — 
Balance, March 31, 2022613 $28.90 4.8
Number of OptionsWeighted Average Exercise PriceWeighted
Average
Remaining
Contractual
Term
(Years)
Balance, December 31, 2022613 $28.90 4.0
Granted459 5.72 10.0
Exercised  — 
Forfeited  — 
Balance, March 31, 20231,072 $18.98 6.4
Exercisable613 
Equity-based compensation cost is recorded within the selling, general and administrative expenses within the condensed consolidated statements of comprehensive loss and was not material for the three months ended March 31, 2023 and 2022. The weighted average grant-date fair values of options granted during the three months ended March 31, 2023 and 2022 were $4.07 and $0, respectively. There were no stock options exercised during 2023 or 2022.
Performance-Based Restricted Stock Agreements
The shares issued pursuant to the Performance-Based Restricted Stock Agreements vest depending on if the performance obligations are met. In general, the performance-based stock units (“Performance PSUs”) will be earned based on achievement of pre-established financial and operational performance objectives and will vest on the date the attainment of such performance objectives as determined by the Compensation Committee (the “Committee”) of the Board of Directors (the “Board”), subject to the participant’s continued employment with the Company. The Company has also issued PSUs that vest if the market price of the Company’s common stock exceeds a defined target during the performance period (“Market PSUs”, together with the Performance PSUs, the “PSUs”).
The Company issued 0.4 million and 0.9 million PSUs for the three months ended March 31, 2023, and 2022, respectively. As of March 31, 2023, the performance-based provision has not been achieved for any of the outstanding performance-based awards.
The Company recognizes compensation expense for the Performance PSUs equal to the fair value of the equity-based compensation awards and is recognized on a straight-line basis over the vesting period of such awards as
19

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
the Company has concluded the performance condition is probable to be met. The fair value of the awards is equal to the fair value of the Company’s common stock at the date of grant.
A summary of the PSU activity for the three months ended March 31, 2023 and 2022 is as follows (in thousands except per share data):
Number of PSUsWeighted Average Exercise PriceWeighted average remaining recognition period
Balance, December 31, 2021424 $18.65 2.0
Granted853 7.24 
Vested  
Forfeited(14)19.33 
Balance, March 31, 20221,263 $10.93 2.3
Number of PSUsWeighted Average Exercise PriceWeighted average remaining recognition period
Balance, December 31, 20221,060 $10.87 1.7
Granted357 6.00 
Vested  
Forfeited(4)7.24 
Balance, March 31, 20231,413 $9.64 1.9
Equity-based compensation cost is recorded within the selling, general and administrative expenses within the consolidated statements of comprehensive loss, and was not material for the three months ended March 31, 2023 and 2022.

NOTE 6 - WARRANTS
RTI Warrants
RTI Global (“RTI”) holds warrants to purchase 971 thousand shares of PCT common stock. RTI can exercise these warrants as of March 17, 2022. The warrants expire on December 31, 2024. The Company determined the warrants are liability classified under ASC 480. Accordingly, the warrants were held at their initial fair value and will be remeasured at fair value at each subsequent reporting date with changes in the fair value presented in the statements of comprehensive loss.
20

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
A summary of the RTI warrant activity for the three months ended March 31, 2023 and 2022 is as follows (in thousands, except per share data, as adjusted to show the effect of the reverse recapitalization as described in Note 1):
Number of warrantsWeighted average exercise priceWeighted average grant date fair valueWeighted average remaining contractual term (years)
Outstanding at December 31, 2021971 $5.56 $0.03 3.0
Granted — — — 
Exercised — — — 
Outstanding at March 31, 2022971 $5.56 $0.03 2.8
Exercisable971 
Number of warrantsWeighted average exercise priceWeighted average grant date fair valueWeighted average remaining contractual term (years)
Outstanding at December 31, 2022971 $5.56 $0.03 2.0
Granted — — — 
Exercised — — — 
Outstanding at March 31, 2023971 $5.56 $0.03 1.8
Exercisable971 
The Company recognized $0.1 million and $1.3 million of benefit for the three months ended March 31, 2023 and 2022, respectively. Refer to Note 12 – Fair Value of Financial Instruments for further information.
Public Warrants and Private Warrants
The Company has outstanding public and private warrants which entitle each holder to exercise its warrants only for a whole number of shares of Common Stock. Each whole warrant entitles the registered holder to purchase one whole share of the Company’s Common Stock at a price of $11.50 per share at the later of the closing of the Business Combination or one year after ROCH’s initial public offering, provided that the Company has an effective registration statement under the Securities Act covering the shares of Common Stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. The warrants will expire five years after March 17, 2021, or earlier upon redemption or liquidation. The private warrants are identical to the public warrants, except that the private warrants and the common stock issuable upon exercise of the private warrants were not transferable, assignable or salable until after March 17, 2021, subject to certain limited exceptions. Additionally, the private warrants are non-redeemable so long as they are held by the initial holder or any of its permitted transferees. If the private warrants are held by someone other than the initial holder or its permitted transferees, the private warrants will be redeemable by the Company and exercisable by such holders on the same basis as the public warrants.
The Company may redeem the outstanding warrants in whole, but not in part, at a price of $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20-trading days within a 30-trading day period ending three business days before the Company sends the notice of redemption to the warrant holders. If the Company calls the warrants for redemption, management will have the option to require all holders that wish to exercise the warrants to do so on a cashless basis. In no event will the Company be required to net cash settle the warrant exercise. The public warrants are accounted for as equity classified warrants as they were determined to be indexed to the Company’s stock and meet the requirements for equity classification.
21

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
The Company has classified the private warrants as a warrant liability as there is a provision within the warrant agreement that allows for private warrants to be exercised via a cashless exercise while held by the Sponsor and affiliates of the Sponsor, but would not be exercisable at any time on a cashless basis if transferred and held by another investor. Therefore, the Company will classify the private warrants as a liability pursuant to ASC 815 until the private warrants are transferred from the initial purchasers or any of their permitted transferees.
There were approximately 5.7 million Public Warrants and 0.2 million Private Placement Warrants outstanding at March 31, 2023 and 2022. The Company recognized $0.1 million of expense and $0.2 million of benefit related to the Private Warrants for the three months ended March 31, 2023 and 2022, respectively. Refer to Note 12 - Fair Value of Financial Instruments for further information.
Series A Warrants
Upon the closing of the 2022 PIPE Offering, the Company issued approximately 17.9 million Series A Warrants to the 2022 PIPE Investors to purchase shares of the Company’s common stock. Each whole warrant entitles the registered holder to purchase one whole share of the Company’s Common Stock at a price of $11.50 per share any time after September 17, 2022 (the “Initial Exercise Date”), provided that the Company has an effective registration statement under the Securities Act covering the shares of Common Stock issuable upon exercise of the warrants and a current prospectus relating to them is available and such shares are registered, qualified or exempt from registration under the securities, or blue sky, laws of the state of residence of the holder. Pursuant to the warrant agreement, a warrant holder may exercise its warrants only for a whole number of shares of Common Stock. The warrants will expire on March 17, 2026.
The Company may redeem the outstanding Series A Warrants in whole, but not in part, at a price of $0.01 per warrant upon a minimum of 30 days’ prior written notice of redemption, if and only if the last sale price of the Company’s common stock equals or exceeds $18.00 per share for any 20-trading days within a 30-trading day period commencing after the Series A Warrants become exercisable and ending three business days before the Company sends the notice of redemption to the warrant holders. If the Company calls the Series A Warrants for redemption, management will have the option to require all holders that wish to exercise the warrants to do so on a cashless basis. In no event will the Company be required to net cash settle the warrant exercise.
The agreements governing the Series A Warrants (the “Series A Warrant Agreements”) provide for a Black Scholes value calculation (“Black Scholes Value”) in the event of certain transactions (“Fundamental Transactions”), which includes a floor on volatility utilized in the value calculation at 100% or greater. The Company has determined this provision introduces leverage to the holders of the Series A Warrants that could result in a value that would be greater than the settlement amount of a fixed-for-fixed option on the Company’s own equity shares. Therefore, the Company will classify the Series A Warrants as a liability pursuant to ASC 815.

As of March 31, 2023, there were approximately 17.9 million Series A Warrants outstanding. The Company recognized $4.8 million and $7.3 million of expense related to the Series A Warrants for the three months ended March 31, 2023 and 2022, respectively. Refer to Note 12 – Fair Value of Financial Instruments for further information.
NOTE 7 – RELATED PARTY TRANSACTIONS
Sylebra Credit Facility
On March 15, 2023, PCT entered into the Revolving Credit Facility pursuant to the Revolving Credit Agreement with the Guarantors, Lenders, and the Administrative Agent, which matures on June 30, 2024. The Lenders and their affiliates are greater than 5% beneficial owners of PCT. Refer to Note 3 - Notes Payable and Debt Instruments for further information.
NOTE 8 – NET LOSS PER SHARE
The Company follows the two-class method when computing net loss per common share when shares are issued that meet the definition of participating securities. The two-class method requires income available to common shareholders for the period to be allocated between common and participating securities based upon their
22

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
respective rights to receive dividends as if all income for the period had been distributed. The two-class method also requires losses for the period to be allocated between common and participating securities based on their respective rights if the participating security contractually participates in losses. As holders of participating securities do not have a contractual obligation to fund losses, undistributed net losses are not allocated to nonvested restricted stock for purposes of the loss per share calculation.
Presented in the table below is a reconciliation of the numerator and denominator for the basic and diluted earnings per share (“EPS”) calculations for the three months ended March 31, 2023 and 2022 (in thousands, except per share data):
Three months ended March 31,
20232022
Numerator:
Net loss$(25,842)$(25,432)
Denominator:— 
Weighted average common shares outstanding, basic and diluted163,588 133,244 
Net loss per share attributable to common stockholder, basic and diluted$(0.16)$(0.19)
The weighted-average outstanding common share equivalents were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive. As of March 31, 2023 and 2022, the Company had outstanding instruments of approximately 24.7 million and 24.7 million vested but not exercised warrants, 0.6 million and 0.6 million vested but not exercised stock options, 3.5 million and 2.9 million non-vested restricted stock units, 1.4 million and 1.3 million non-vested performance stock units, and 4.0 million and 4.0 million contingently-issuable shares related to the Earnout which could be dilutive to the calculation in the future, respectively.
NOTE 9 – PROPERTY, PLANT AND EQUIPMENT
Presented in the table below are the major classes of property, plant and equipment by category as of the below dates:
As of March 31, 2023
(in thousands)CostAccumulated DepreciationNet Book Value
Building$12,534 $1,106 $11,428 
Machinery and equipment33,132 7,681 25,451 
Leasehold Improvements2,957 961 1,996 
Fixtures and Furnishings628 105 523 
Land improvements150 25 125 
Land1,150  1,150 
Construction in process538,912  538,912 
Total property, plant and equipment$589,463 $9,878 $579,585 
23

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
As of December 31, 2022
(in thousands)CostAccumulated
Depreciation
Net Book Value
Building$12,534 $1,016 $11,518 
Machinery and equipment23,728 6,674 17,054 
Leasehold Improvements2,957 803 2,154 
Fixtures and Furnishings529 83 446 
Land improvements150 22 128 
Land1,150  1,150 
Construction in process473,269  473,269 
Total property, plant and equipment$514,317 $8,598 $505,719 
Depreciation expense is recorded within operating costs in the condensed consolidated statements of comprehensive loss and amounted to $1.3 million and $0.8 million for the three months ended March 31, 2023 and 2022, respectively.
NOTE 10 – DEVELOPMENT PARTNER ARRANGEMENTS
License Agreements
On October 16, 2015, Legacy PCT entered into a patent license agreement with P&G (the “Original Patent License Agreement”). Legacy PCT and P&G entered into an Amended and Restated Patent License Agreement on July 28, 2020 (the “Amended and Restated Patent License Agreement”). PCT and P&G entered into a side letter agreement on February 12, 2021 amending certain provisions of the Amended and Restated License Agreement (the “Side Letter Agreement” and, together with the Original Patent License Agreement and the Amended and Restated Patent License Agreement, the “License Agreement”). The License Agreement outlines three phases with specific deliverables for each phase. During Phase 1 of the License Agreement, P&G provided Legacy PCT with up to one full-time employee to assist in the execution of Legacy PCT’s research and development activities. During Phase 2, P&G provided up to two full-time employees to assist in the execution of Legacy PCT’s research and development activities. In April 2019, Legacy PCT elected to enter into Phase 3 of the License Agreement and prepaid a royalty payment in the amount of $2.0 million, which will be reduced against future royalties payable as sales occur. Phase 3 of the License Agreement relates to the commercial manufacture period for the manufacture of the licensed product. This phase includes the construction of the first commercial plant for the manufacture of the licensed product, details on the commercial sales capacity and the pricing of the licensed product to P&G and to third parties. Where the Company has made royalty payments to its product development partners, the Company expenses such payments as incurred unless it has determined that is it probable that such prepaid royalties have future economic benefit to the Company. In such cases prepaid royalties will be reduced as royalties would otherwise be due to the partners.
Effective April 1, 2023, the Company and P&G executed a Second Side Letter, dated March 27, 2023, amending the date by which commercial sales must be maintained at 70% of nameplate capacity under Section 4.4 of the License Agreement from April 15, 2023 to December 31, 2024.
As of March 31, 2023 and December 31, 2022, the Company is in Phase 3 of the License Agreement and has recorded $2.0 million within prepaid expenses and other non-current assets in the condensed consolidated balance sheets.
On November 13, 2019, Legacy PCT entered into a patent sublicense agreement with Impact Recycling Limited (“Impact”) through the term of the patents. The agreement outlines an initial license fee of $2.5 million and royalties on production using the license. In 2020, Legacy PCT paid $0.9 million of the initial license fee, and during the year ended December 31, 2021, the Company paid the remaining $1.6 million of the initial fee. The initial license fee of $2.5 million is recorded in prepaid expenses and other non-current assets in the condensed consolidated balance sheets and will be ratably amortized over the term of the underlying patent using the straight-line method. In May 2021, the Company began using the technology covered by the Impact agreement and commenced amortization as of this date.
24

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
Block and Release Agreement
On June 23, 2020, Legacy PCT entered into a block and release agreement with Total Petrochemicals & Refining S.A./N.V. (“Total”). Upon execution of the agreement, Total made a prepayment consisting of a payment of $5.0 million for future receipt of resin consisting of recycled polypropylene (“recycled PP”). The prepayment was placed in an escrow account until the “release condition” of the Company closing the bond offering and overall capital funding of at least $370.0 million has occurred. After the Company successfully raised the required capital, the $5.0 million was released to the Company in 2021 and recorded as deferred revenue in the condensed consolidated balance sheets.
Strategic Alliance Agreement
On December 13, 2018, Legacy PCT entered into a strategic alliance agreement with Nestle Ltd. (“Nestle”), which expires on December 31, 2023. Upon execution of the agreement, Nestle committed to provide $1.0 million to fund further research and development efforts. The funding provided by Nestle may be convertible, in whole or in part, into a prepaid product purchase arrangement at Nestle’s option, upon the time of product delivery beginning in 2022. Additionally, because the research and development efforts were not successful as of December 31, 2020, up to 50% of the funding may be convertible into a 5-year term loan obligation, payable to Nestle at an interest rate equivalent to the U.S. prime rate. As of the issuance of these statements, Nestle has not elected to convert any funding into a term loan.

PCT received the funding from Nestle on January 8, 2019. The Company has recorded $1.0 million as a deferred research and development obligation within other non-current liabilities in the condensed consolidated balance sheets as of March 31, 2023 and December 31, 2022. Recognition related to the funding received will be deferred until it is probable that Nestle will not exercise their option. If the prepaid product purchase option is exercised, the obligation will be recognized as an adjustment to the transaction price of future product sales (e.g., net revenue presentation). If the option is not exercised, or in the case of development efforts not being successful, any amounts not converted to a loan obligation will be recognized as a reduction to research and development costs.
NOTE 11 - INCOME TAXES
The Company has determined that any net deferred tax assets are not more likely than not to be realized in the future, and a full valuation allowance is required. In addition, the Company has determined that any current forecasted operations would result in federal and state income tax losses which are also not more likely than not to be realized. As a result, for the periods ended March 31, 2023 and 2022, the Company has reported tax expense of $0 and $0, respectively.
Management has evaluated the Company’s tax positions and has determined that the Company has taken no uncertain tax positions that require adjustment to the condensed consolidated interim financial statements for the respective periods.
NOTE 12 – FAIR VALUE OF FINANCIAL INSTRUMENTS
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date and sets out a fair value hierarchy. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). Inputs are broadly defined as assumptions market participants would use in pricing an asset or liability. Assets and liabilities carried at fair value are classified and disclosed in one of the following three categories:
Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date.
Level 2 - Inputs other than quoted prices within Level 1 that are observable for the asset or liability, either directly or indirectly, and fair value is determined through the use of models or other valuation methodologies
25

PureCycle Technologies, Inc.
NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS — CONTINUED
(Unaudited)
Level 3 - Inputs are unobservable for the asset or liability and include situations where there is little, if any, market activity for the asset or liability. The inputs into the determination of fair value are based upon the best information in the circumstances and may require significant management judgment or estimation.
Assets and liabilities measured and recorded at Fair Value on a recurring basis
As of March 31, 2023 and December 31, 2022, the Company’s financial assets and liabilities measured and recorded at fair value on a recurring basis were classified within the fair value hierarchy as follows (in thousands):
March 31, 2023December 31, 2022
Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets
Cash equivalents$ $ $ $ $51,250 $ $ $51,250 
Restricted cash equivalents - current68,028   68,028 68,850   68,850 
Restricted cash equivalents - noncurrent157,466   157,466 94,781   94,781 
Investments:
Commercial paper, available for sale     32,756  32,756 
Corporate Bonds, available for sale     58,442  58,442 
Municipal bonds, available for sale     7,394  7,394 
Total investments     98,592  98,592 
Liabilities
Warrant liability:
RTI warrants$ $ $3,612 $3,612 $ $ $3,670 $3,670 
Private warrants  856 856   784 784 
Series A warrants 56,250  56,250  51,429  51,429 
Total warrant liability$ $56,250 $4,468 $60,718 $ <